Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-08-24
2008-10-28
Rao, Deepak (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S241000, C514S248000, C514S252020, C514S252110, C514S255050, C514S266200, C514S275000, C544S120000, C544S122000, C544S295000, C544S296000, C544S331000, C544S332000
Reexamination Certificate
active
07442699
ABSTRACT:
Compounds having activity as inhibitors of IKK are disclosed, particularly IKK-2. The compounds of this invention are anilinopyrimidine derivatives having the following structure:wherein R1and R6are as defined herein. Such compounds have utility in the treatment of a wide range of conditions that are responsive to IKK inhibition. Thus, methods of treating such conditions are also disclosed, as are pharmaceutical compositions containing one or more compounds of the above compounds.
REFERENCES:
patent: 4788195 (1988-11-01), Torley et al.
patent: 4876252 (1989-10-01), Torley et al.
patent: 4966622 (1990-10-01), Rempfler et al.
patent: 4973690 (1990-11-01), Rempfler et al.
patent: 5159078 (1992-10-01), Remplfler et al.
patent: 5166047 (1992-11-01), Hioki et al.
patent: 5262527 (1993-11-01), Gregory et al.
patent: 5489505 (1996-02-01), Kato et al.
patent: 5516775 (1996-05-01), Zimmermann et al.
patent: 5527914 (1996-06-01), Hioli et al.
patent: 5942384 (1999-08-01), Arai et al.
patent: 6114333 (2000-09-01), Davis et al.
patent: 6552029 (2003-04-01), Davis et al.
patent: 6693108 (2004-02-01), Green et al.
patent: 7122544 (2006-10-01), Kois et al.
patent: 7129242 (2006-10-01), Satoh et al.
patent: WO 93/08167 (1993-04-01), None
patent: WO 95/09853 (1995-04-01), None
patent: WO 98/18782 (1998-05-01), None
patent: WO 98/20003 (1998-05-01), None
patent: WO 99/01439 (1999-01-01), None
patent: WO 99/53927 (1999-10-01), None
patent: WO 99/63821 (1999-12-01), None
patent: WO 00/12486 (2000-03-01), None
patent: WO 00/15657 (2000-03-01), None
patent: WO 00/31067 (2000-06-01), None
patent: WO 00/33844 (2000-06-01), None
patent: WO 00/39101 (2000-07-01), None
patent: WO 00/43373 (2000-07-01), None
patent: WO 00/56738 (2000-09-01), None
patent: WO 00/75118 (2000-12-01), None
patent: WO 00/78731 (2000-12-01), None
patent: WO 01/12621 (2001-02-01), None
patent: WO 01/14375 (2001-03-01), None
patent: WO 01/23382 (2001-04-01), None
patent: WO 01/27089 (2001-04-01), None
patent: WO 01/29009 (2001-04-01), None
patent: WO 01/91749 (2001-12-01), None
patent: WO 02/46170 (2002-06-01), None
patent: WO 02/085396 (2002-10-01), None
Casanova et al., PubMed Abstract (Rev Neurol. 28(9):909-15), May 1999.
Douglas, Jr. Introduction to Viral Diseases, Cecil Textbook of Medicine, 20thEdition, vol. 2, pp. 1739-1747, 1996.
Damasio, Alzheimer's Disease and related dementias, Cecil Textbook of Medicine, 20thEdtion, vol. 2, pp. 1992-1996, 1996.
Simone, Oncology: Introduction, Cecil Textbook of Medicine, 20thEdition, vol. 1, pp. 1004-1010, 1996..
Aspenstrom et al., “Two GTPases, Cdc42 and Rac, bind directly to a protein implicated in the immunodeficiency disorder Wiskott-Aldrich syndrome”,Curr. Biol.6:70-77 (1996).
Baeuerle and Baichwal, “NF-kappa B as a frequent target for immunosuppressive and anti-inflammatory molecules”,Advances in Immunology 65:111-137 (1997).
Beg et al., “Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-kappa B”,Nature376(6536):167-70 (1995).
Bohrer et al., “Role of NFkappaB in the mortality of sepsis.”,J. Clin. Inv.100:972-985 (1997).
Brand et al., “Activated transcription factor nuclear factor-kappa B is present in the atherosclerotic lesion”,J Clin Inv.97:1715-1722 (1997).
Burke et al., “Peptides corresponding to the N and C termini of IkappaB-alpha, -beta, and -epsilon as probes of the two catalytic subunits of IkappaB kinase, IKK-1 and IKK-2”,Journal of Biological Chemistry 274:36146-36152 (1999).
Chen et al., “Activation and inhibition of the AP-1 complex in human breast cancer cells”,Mol. Carcinogenesis15:215-226 (1996).
Cramer et al., “A firm hand on NFkappaB: structures of the IkappaBalpha-NFkappaB complex”,Structure 7:R1-R6 (1999).
Davis et al.,Chemical Abstracts129:4655 (1998).
Deacon et al., “MEK kinase 3 directly activates MKK6 and MKK7, specific activators of the p38 and c-Jun NH2-terminal kinases”,J. Biol. Chem.274:16604-16610 (1999).
Delhase et al., “Positive and negative regulation of IkappaB kinase activity through IKKbeta subunit phosphorylation”,Science284:309 313 (1999).
Dong et al., “Defective T cell differentiation in the absence of Jnk1”,Science282:2092-2095 (1998).
Faris et al., “Regulation of interleukin-2 transcription by inducible stabile expression of dominant negative and dominant active mitogen-activated protein kinase kinase kinase in Jurkat T cells”,J. Biol Chem.271:27366-27373 (1996).
Gosset et al., “Expression of E-selectin, ICAM-1 and VCAM-1 on bronchial biopsies from allergic and non-allergic asthmatic patients”,Int Arch Allergy Immunol. 106:69-77 (1995).
Green et al.,Chemical Abstracts134:178569 (2001).
Gum et al., “Regulation of 92 kDa type IV collagenase expression by the jun aminoterminal kinase- and the extracellular signal-regulated kinase-dependent signaling cascades”,Oncogene14:1481-1493 (1997).
Han et al., “Jun N-terminal kinase in rheumatoid arthritis”,J. Pharm. Exp. Therap.291:124-130 (1999).
Hibi et al., “Identification of an oncoprotein- and UV-responsive protein kinase that binds and potentiates the c-Jun activation domain”, M.Genes Dev.7:2135-2148 (1993).
Hirosumi et al., “A central role for JNK in obesity and insulin resistance”,Letters to Nature420:333-336 (2002).
Hu et al., “Abnormal morphogenesis but intact IKK activation in mice lacking the IKKalpha subunit of IkappaB kinase”,Science284:316-320 (1999).
Ishizuka et al., “Mast cell tumor necrosis factor alpha production is regulated by MEK kinases”,Proc. Nat. Acad. Sci.USA 94:6358-6363 (1997).
Karin et al., “AP-1 function and regulation”,Curr Opin Cell Biol9:240-246 (1997).
Koch et al., “Angiogenesis mediated by soluble forms of E-selectin and vascular cell adhesion molecule-1”,Nature376:517-519 (1995).
Lange-Carter et al., “A divergence in the MAP kinase regulatory network defined by MEK kinase and Raf.”,Science260:315-319 (1993).
Li et al., “Blocked signal transduction to the ERK and JNK protein kinases in anergic CD4+T cells”,Science271:1272-1276 (1996).
Li et al., “The Ras-JNK pathway is involved in shear-induced gene expression”,Mol. Cell. Biol.16:5947-5954 (1996).
Li et al., “IKK1-deficient mice exhibit abnormal development of skin and skeleton”,Genes&Development13:1322-1328 (1999).
Li et al., “Severe liver degeneration in mice lacking the IkappaB kinase 2 gene.”,Science 284:321-324 (1999).
Lin et al., “Identification of a dual specificity kinase that activates the Jun kinases and p38-Mpk2”,Science268:286-289 (1995).
Malinin et al., MAP3K-related kinase involved in NF-kappaB induction by TNF, CD95 and IL-1,Nature 385:540-544 (1997).
Manning et al., “Transcription inhibitors in inflammation”,Exp. Opin. Invest. Drugs6:555-567 (1997).
Mercurio et al., “IKK-1 and IKK-2: cytokine-activated IkappaB kinases essential for NF-kappaB activation”,Science278:860-866 (1997).
Mercurio et al., “IkappaB kinase (IKK)-associated protein 1, a common component of the heterogeneous IKK complex”,Mol Cell Biol.19:1526-1538 (1999).
Milne et al., “p53 is phosphorylated in vitro and in vivo by an ultraviolet radiation-induced protein kinase characteristic of the c-Jun kinase, JNK1”,J. Biol Chem.270:5511-5518 (1995).
Mohit et al., “p493F12 kinase: a novel MAP kinase expressed in a subset of neurons in the human nervous system”, C.A.Neuron14:67-75 (1995).
Nishina et al., “Impaired CD28-mediated interleukin 2 production and proliferation in stress kinase SAPK/ERK1 kinase (SEK1)/mitogen-activated protein kinase kinase 4 (MKK4)-deficient T lymphocytes”,J. Exp. Med.186:941-953 (1997).
Okamoto et al., “Selective activation of the JNK/AP-1 pathway in Fas-mediated apoptosis of rheumatoid arthritis synoviocytes”,Art
Bhagwat Shripad S.
Erdman Paul E.
Kois Adam
MacFarlane Karen J.
Palanki Moorthy S. S.
Jones Day
Rao Deepak
Signal Pharmaceuticals LLC
LandOfFree
Anilinopyrimidine derivatives as IKK inhibitors and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anilinopyrimidine derivatives as IKK inhibitors and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anilinopyrimidine derivatives as IKK inhibitors and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4018482